Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DREAMM-5 platform study of belantamab mafodotin alone and in combinations for relapsed/refractory multiple myeloma
MOH_2022-09-28_011980Phase 2Not yet recruiting
- Sponsor
- GSK
- Start
- Sep 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of belantamab mafodotin, nirogacestat, isatuximab, lenalidomide, pomalidomide and 1 more in multiple myeloma (MM) (9 arms), sponsored by GSK. Planned start Sep 2022; status: not yet recruiting.
02
Drugs
belantamab mafodotinnirogacestatisatuximablenalidomidepomalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on MOH_2022-09-28_011980.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-09-28_011980.